EMEA fortsatte den gensidige kontakt med USA' s Food and Drug Administration, ikke kun via arbejdet med ICH- processen, men ligeledes inden for rammerne af den transatlantiske virksomhedsdialog mellem USA og EU.
received a COMP opinion in 2001 are developed for the treatment of cancers, diseases of immunological origin and metabolic diseases of which a number are related to enzyme deficiencies.